Show Summary Details
Page of

The current and future outlook for patients with axial spondyloarthritis 

The current and future outlook for patients with axial spondyloarthritis
Chapter:
The current and future outlook for patients with axial spondyloarthritis
Author(s):

Stefan Siebert

, Sengupta Raj

, and Alexander Tsoukas

DOI:
10.1093/med/9780198755296.003.0016
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2020. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 30 September 2020

There have been major advances in axial spondyloarthritis (axSpA) over the past decade. The current and future outlook for patients with axSpA is therefore much improved and largely positive. Despite this, there is still significant unmet need in pathophysiology, prevention, diagnosis, and treatment. While several new therapeutic agents are expected to reach the clinic over the next few years, the treatment of individual patients is likely to remain largely empiric. There is a need for the development of biomarkers and rationale stratified treatment approaches in order to capitalise on previous gains for the benefit of our patients.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.